Additional Relevant Details Upon closing of the Transaction, Impax is expected to add:

• A portfolio of 15 currently marketed generic products;
• One approved generic product and two approved strengths of a currently marketed product, which have not yet launched;
• One pipeline generic product and one pipeline strength of a currently marketed product, which are pending U.S. Food and Drug Administration (FDA) approval;
• The full commercial rights to Impax's pending ANDA for the generic equivalent to Concerta (methylphenidate hydrochloride), a product previously partnered with Teva; and
• One generic product under development.